DALLAS / Feb 08, 2024 / Business Wire / Enhabit, Inc. (NYSE: EHAB), a leading national home health and hospice provider, today announced it will report its results for the fourth quarter ended Dec. 31, 2023, on March 6, 2024, and host a webcast and conference call on March 7, 2024. Individuals who would like to participate in the conference call webcast should join 15 minutes before the scheduled start time.
A link to the webcast of the conference call and online replay can be found on Enhabit’s investor website.
About Enhabit Home Health & Hospice
Enhabit Home Health & Hospice (Enhabit, Inc.) is a leading national home health and hospice provider working to expand what's possible for patient care in the home. Enhabit’s team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 255 home health locations and 110 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit ehab.com.
| Last Trade: | US$9.68 |
| Daily Change: | 0.08 0.83 |
| Daily Volume: | 489,536 |
| Market Cap: | US$489.900M |
November 05, 2025 August 06, 2025 May 07, 2025 November 06, 2024 | |

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load